Vaccine provides welcome boost for value

Last week’s news that the Pfizer/BioNTech vaccine is effective at preventing Covid-19 was a huge boost for everyone, including the stock market. But not all parts of the market responded in the same way. Specifically, the news triggered a swift rotation from growth to value, as the table below shows.


While the update on the vaccine is clearly great news, the sharp share price moves were really a reflection of just how polarised markets have become.

A range of “work from home” stocks, whose shares have directly benefited from the pandemic over the last six months or so, saw prices lurch downwards. By contrast, a host of hitherto downtrodden and unloved businesses were leading markets upwards.

In our view, the main lesson to take from all this is not the identities of the risers and fallers, but that when good news is priced into a stock, any bad news can have a disproportionately negative effect. Similarly, when you have bought a business on a cheap valuation, a little good news can go a very long way.

The rotation reminds us that just as stocks that are “priced for perfection” eventually disappoint, so cheap stocks – those trading at a discount to their underlying intrinsic value - are unlikely to stay cheap forever.

Even after last week’s bounce, 2020 has still been a dismal year for value, as the chart below shows.


Value stocks continue to trade close to all-time lows compared to growth stocks and far below their long-run average, as the chart below shows. We do not profess to know if the tide has turned but we do think there is a huge opportunity for mean reversion. Investors who have all their eggs in the growth basket could find they miss out, as and when that reversion comes.


Important Information:
This material has been issued by Schroder Investment Management Australia Limited (ABN 22 000 443 274, AFSL 226473) (Schroders) for information purposes only. It is intended solely for professional investors and financial advisers and is not suitable for distribution to retail clients. The views and opinions contained herein are those of the authors as at the date of publication and are subject to change due to market and other conditions. Such views and opinions may not necessarily represent those expressed or reflected in other Schroders communications, strategies or funds. The information contained is general information only and does not take into account your objectives, financial situation or needs. Schroders does not give any warranty as to the accuracy, reliability or completeness of information which is contained in this material. Except insofar as liability under any statute cannot be excluded, Schroders and its directors, employees, consultants or any company in the Schroders Group do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this material or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this material or any other person. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. Any references to securities, sectors, regions and/or countries are for illustrative purposes only. You should note that past performance is not a reliable indicator of future performance. Schroders may record and monitor telephone calls for security, training and compliance purposes.

Contact Schroders

Schroders is a world-class asset manager operating from 35 locations across Europe, the Americas, Asia, the Middle East and Africa.

Worldwide locations

For any further questions, please contact us.

Contact us

Our sales team is available to discuss with you any investment options and opportunities you might be interested in.

Your contacts